Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06NRQ
|
|||
| Drug Name |
1,2-diamino cyclopentane-based derivative 18
|
|||
| Synonyms |
PMID26593218-Compound-40
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H20F2N6OS
|
|||
| Canonical SMILES |
CN(C1CCCC1NC2=NC3=C(S2)C=C(C=C3)F)C(=O)C4=C(C=CC(=C4)F)N5N=CC=N5
|
|||
| InChI |
1S/C22H20F2N6OS/c1-29(21(31)15-11-13(23)6-8-18(15)30-25-9-10-26-30)19-4-2-3-16(19)27-22-28-17-7-5-14(24)12-20(17)32-22/h5-12,16,19H,2-4H2,1H3,(H,27,28)/t16-,19-/m0/s1
|
|||
| InChIKey |
AWDZNHIULYTTNC-LPHOPBHVSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Orexin receptor type 1 (HCRTR1) | Target Info | Antagonist | [1] |
| Orexin receptor type 2 (HCRTR2) | Target Info | Antagonist | [1] | |
| Target's Patent Info | Orexin receptor type 1 (HCRTR1) | Target's Patent Info | [1] | |
| Orexin receptor type 2 (HCRTR2) | Target's Patent Info | [1] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | G alpha (q) signalling events | |||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.